Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient-Reply
JAMA Cardiol
.
2021 Sep 1;6(9):1097.
doi: 10.1001/jamacardio.2021.1589.
Authors
Mark Trinder
1
2
,
Pradeep Natarajan
2
3
4
5
Affiliations
1
Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.
2
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard, Cambridge, Massachusetts.
3
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston.
4
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
5
Cardiovascular Research Center, Massachusetts General Hospital, Boston.
PMID:
34106217
DOI:
10.1001/jamacardio.2021.1589
No abstract available
Publication types
Letter
Comment
MeSH terms
Cholesterol, LDL
Humans
Lipoprotein(a)*
Mass Screening*
Substances
Cholesterol, LDL
Lipoprotein(a)